We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11B
AUM Growth
+$1.14B
Cap. Flow
+$217M
Cap. Flow %
1.96%
Top 10 Hldgs %
40.32%
Holding
138
New
6
Increased
33
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$152M
2
GILD icon
Gilead Sciences
GILD
+$129M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$102M
4
PBYI icon
Puma Biotechnology
PBYI
+$81.9M
5
ESRX
Express Scripts Holding Company
ESRX
+$72M

Top Sells

Rank Stock Value
1
MOH icon
Molina Healthcare
MOH
+$168M
2
SHPG
Shire pic
SHPG
+$85.9M
3
MCK icon
McKesson
MCK
+$66.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$66.1M
5
COO icon
Cooper Companies
COO
+$55.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Financials 0.18%
3 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
76
Xencor
XNCR
$1.48B
$16.2M 0.15%
1,107,022
-23,000
-2% -$309K
BMRN icon
77
BioMarin Pharmaceuticals
BMRN
$12B
$15.6M 0.14%
149,000
-39,000
-21% -$4.07M
SVA
78
DELISTED
Sinovac Biotech, Ltd
SVA
$15.3M 0.14%
2,667,500
– –
ZBH icon
79
Zimmer Biomet
ZBH
$18.5B
$15.1M 0.14%
151,204
-67,465
-31% -$6.6M
LKFT
80
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$14.5M 0.13%
230,000
-282,900
-55% -$14.5M
NTRA icon
81
Natera
NTRA
$36.1B
$13.8M 0.12%
1,276,190
– –
CAH icon
82
Cardinal Health
CAH
$54.5B
$13M 0.12%
146,000
– –
EHTH icon
83
eHealth
EHTH
$43.2M
$13M 0.12%
1,300,000
– –
SGYP
84
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$12.9M 0.12%
2,276,648
– –
JAZZ icon
85
Jazz Pharmaceuticals
JAZZ
$16.1B
$12.7M 0.11%
90,000
-25,000
-22% -$3.46M
NBRV
86
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$12.7M 0.11%
5,260
– –
IMMU
87
DELISTED
Immunomedics Inc
IMMU
$11.7M 0.11%
3,802,000
+479,000
+14% +$1.34M
ENSG icon
88
The Ensign Group
ENSG
$10.7B
$11.2M 0.1%
529,369
– –
BXLT
89
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$11.1M 0.1%
285,000
– –
CLLS
90
Cellectis
CLLS
$286M
$10.9M 0.1%
350,000
– –
ASMB icon
91
Assembly Biosciences
ASMB
$507M
$10.5M 0.1%
116,425
– –
MGNX icon
92
MacroGenics
MGNX
$245M
$9.82M 0.09%
317,000
– –
ABT icon
93
Abbott
ABT
$187B
$9.48M 0.09%
211,000
– –
VTAE
94
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$8.82M 0.08%
487,400
+125,900
+35% +$1.73M
SIEN
95
DELISTED
Sientra, Inc.
SIEN
$8.04M 0.07%
135,750
-162,250
-54% -$8.43M
IOVA icon
96
Iovance Biotherapeutics
IOVA
$2.1B
$7.89M 0.07%
1,022,100
– –
MDVN
97
DELISTED
MEDIVATION, INC.
MDVN
$7.88M 0.07%
+163,000
New +$7.03M
MRNS
98
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$7.37M 0.07%
+241,250
New +$7.08M
RDHL
99
Redhill Biopharma
RDHL
$4.44M
$7.28M 0.07%
565
– –
AET
100
DELISTED
Aetna Inc
AET
$7.24M 0.07%
67,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2015 Portfolio in Review

As of Q4 2015, OrbiMed held 138 positions worth $11B, up 11% from $9.91B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q4 2015 filing shows 6 new, 33 increased, 26 reduced and 8 closed positions. Its largest new stake was Viatris: 3,157,000 shares worth $171M. The largest sale was Molina Healthcare, an estimated $168M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2015 buy was Viatris: 3,157,000 shares worth $171M.
  • OrbiMed added most to Gilead Sciences in Q4 2015, an estimated $129M increase.
  • OrbiMed's biggest Q4 2015 reduction was Molina Healthcare, cutting an estimated $168M.
  • OrbiMed fully exited Chimerix, Inc. in Q4 2015, selling an estimated $39M.
  • OrbiMed's ten largest holdings make up 40% of its $11B portfolio in Q4 2015.
  • OrbiMed opened 6 new positions and closed 8 in Q4 2015.
  • OrbiMed's portfolio value rose 11% quarter-over-quarter to $11B.

Based on OrbiMed's 13F filing for Q4 2015, filed 16 Feb 2016.